Reimagining reimbursement in radiation oncology

Radiation therapy providers in the US need to start preparing now for the introduction of the Radiation Oncology Alternative Payment Model (RO-APM)

Starting 1 July 2021, the Radiation Oncology Alternative Payment Model (RO-APM) will enable CMS to gather evidence – at scale – on an all-new “financial infrastructure” for radiation oncology services in the US – and crucially whether an alternative payment structure preserves or enhances the quality of care for cancer patients while reducing annual Medicare expenditures.

More information

Details

Route de la Longeraie 9, 1110 Morges, Switzerland

Beth Kaplan

Associated Trend items

Accuray and Limbus AI Inc. Partner to Leverage Limbus' Innovative AI-driven Technology to Enhance Accuray Adaptive Radiotherapy Solutions

Accuray Incorporated (NASDAQ: ARAY) and Limbus AI Inc. announced today they are partnering to augment Accuray adaptive radiotherapy capabilities by leveraging Limbus' artificial intelligence (AI)-driven autocontouring algorithms - enabling automated contouring to further streamline the treatment planning process*.

The companies expect an integrated offering to be made available beginning in 2023. Changes in tumor size, shape and location, or in the position of organs and other healthy tissue due to weight gain or loss during the course of radiation therapy, may require adaptation of the treatment plan to ensure the radiation dose remains targeted on the tumor while avoiding nearb...

More information

Accuray Receives IMV Award for Best In Service in Radiation Oncology for 2022

We announced that our commitment to delivering better, faster cancer treatment technology and superior service is resulting in highly satisfied customers

According to the IMV ServiceTrak™ Radiation Oncology 2022 report, Accuray achieved the highest score in the industry in Overall Service Performance and was recognized for Best Service in Radiation Oncology. The IMV report includes feedback on radiation therapy technologies used in treating cancer patients in the U.S. and specifically, survey respondents with hands-on exp...

More information

Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological Indications

Clinical studies presented at the 15th Congress of the International Stereotactic Radiosurgery Society (ISRS)

Accuray Incorporated announced that new clinical studies presented at the 15th Congress of the International Stereotactic Radiosurgery Society (ISRS) in Milan, Italy reinforce the value of the company's CyberKnife® platform in the treatment of neurological indications with non-invasive radiosurgery. The data highlight the benefits experienced by neurosurgeons for more th...

More information

Products associated

robotic assisted radiosurgery linear particle accelerator

CyberKnife® S7™

3D conformational radiation therapy linear particle accelerator

Radixact®

Compare

Remove all

Compare up to 10 products